{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:23Z","timestamp":1791245183059,"version":"4.1.0"},"reference-count":204,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The increasing efficacy of cancer therapies has significantly improved survival rates, but it has also highlighted the prevalence of cancer-therapy-related cardiac dysfunction (CTRCD). This review provides a comprehensive overview of the identification, monitoring, and management of CTRCD, a condition resulting from several treatments, such as anthracyclines, HER2-targeted therapies, target therapies, and radiotherapy. The paper includes a discussion of the mechanisms of CTRCD associated with various cancer treatments. Early detection through serum biomarkers and advanced imaging techniques is crucial for effective monitoring and risk stratification. Preventive strategies include pharmacological interventions such as ACE inhibitors\/angiotensin receptor blockers, beta-blockers, and statins. Additionally, novel agents like sacubitril\/valsartan, sodium-glucose co-transporter type 2 inhibitors, and vericiguat show promise in managing left ventricular dysfunction. Lifestyle modifications, including structured exercise programs and optimized nutritional strategies, further contribute to cardioprotection. The latest treatments for both asymptomatic and symptomatic CTRCD across its various stages are also discussed. Emerging technologies, including genomics, artificial intelligence, novel biomarkers, and gene therapy, are paving the way for personalized approaches to CTRCD prevention and treatment. These advancements hold great promise for improving long-term outcomes in cancer patients by minimizing cardiovascular complications.<\/jats:p>","DOI":"10.3390\/life15030471","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T08:57:02Z","timestamp":1742201822000},"page":"471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment"],"prefix":"10.3390","volume":"15","author":[{"given":"Carla","family":"Contaldi","sequence":"first","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"D\u2019Aniello","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Panico","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zito","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Di Lorenzo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-6983","authenticated-orcid":false,"given":"Paolo","family":"Golino","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Montesarchio","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14545","DOI":"10.1002\/cam4.5980","article-title":"Current perspectives of cardio-oncology: Epidemiology, adverse effects, pre-treatment screening and prevention strategies","volume":"12","author":"Bychowski","year":"2023","journal-title":"Cancer Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamacardio.2016.2132","article-title":"Oncocardiology\u2014Past, present, and future: A review","volume":"1","author":"Yeh","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluationof adult patients during andafter cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.2017","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: A position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","article-title":"Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review","volume":"80","author":"Baldassarre","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11886-024-02131-5","article-title":"Inflammation in Chemotherapy-Induced Cardiotoxicity","volume":"26","author":"Hutchins","year":"2024","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/phar.2638","article-title":"Chemotherapy-associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies","volume":"41","author":"Veeder","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: An update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ. Res."},{"key":"ref_14","first-page":"452","article-title":"Cancer Therapeutic Drug Guide","volume":"Volume 4","author":"Herrmann","year":"2023","journal-title":"Cardio-Oncology Practice Manual: A Companion to Braunwald\u2019s Heart Disease"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Saiki, H., Petersen Yusuf, S.W., Venkatesulu, B.P., Mahadevan, L.S., and Krishnan, S. (2017). Radiation-induced cardiovascular disease: A clinical perspective. Front. Cardiovasc. Med., 4.","DOI":"10.3389\/fcvm.2017.00066"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.echo.2013.12.005","article-title":"Analysis of left ventricular volumes and function: A multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography","volume":"27","author":"Hoffmann","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.echo.2017.11.013","article-title":"Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update","volume":"31","author":"Porter","year":"2018","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_20","first-page":"677","article-title":"Strain imaging in cardio-oncology","volume":"2","author":"Liu","year":"2020","journal-title":"Cardio Oncol."},{"key":"ref_21","first-page":"977","article-title":"Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50%\u201359% treated with anthracyclines","volume":"16","author":"Mousavi","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.echo.2016.02.018","article-title":"Myocardial strain is associated with adverse clinical cardiac events in patients treated with anthracyclines","volume":"29","author":"Ali","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Contaldi, C., Montesarchio, V., Catapano, D., Falco, L., Caputo, F., D\u2019Aniello, C., Masarone, D., and Pacileo, G. (2023). Multimodality Cardiovascular Imaging of Cardiotoxicity Due to Cancer Therapy. Life, 13.","DOI":"10.3390\/life13102103"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ehjci\/jey188","article-title":"Echocardiographic reference ranges for normal non-invasive myocardial work indices: Results from the EACVI NORRE study","volume":"20","author":"Manganaro","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2022.06.067","article-title":"Deterioration in myocardial work indices precedes changes in global longitudinal strain following anthracycline chemotherapy","volume":"363","author":"Zhan","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jcmg.2022.02.027","article-title":"Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity","volume":"15","author":"Thampinathan","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Moya, A., Buytaert, D., Beles, M., Paolisso, P., Duchenne, J., Huygh, G., Langmans, C., Roelstraete, A., Verstreken, S., and Goethals, M. (2023). Serial Non-Invasive Myocardial Work Measurements for Patient Risk Stratification and Early Detection of Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients: A Single-Centre Observational Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041652"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.21037\/qims-22-817","article-title":"Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. Quant","volume":"13","author":"Li","year":"2023","journal-title":"Imaging Med. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"609194","DOI":"10.1155\/2015\/609194","article-title":"Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy","volume":"2015","author":"Calleja","year":"2015","journal-title":"J. Oncol."},{"key":"ref_32","first-page":"20","article-title":"Detection of right ventricular dysfunction by three-dimensional echocardiography and two-dimensional speckle tracking in breast cancer patients receiving anthracycline-based chemotherapy","volume":"9","author":"Sabry","year":"2023","journal-title":"Cardiooncology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.15190\/d.2019.7","article-title":"Longitudinal strain analysis allows the identification of subclinical deterioration of right ventricular function in patients with cancer therapy-related left ventricular dysfunction","volume":"7","author":"Cherata","year":"2019","journal-title":"Discoveries"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/ehjci\/jes139","article-title":"Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy","volume":"14","author":"Stoodley","year":"2013","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Di Lisi, D., Moreo, A., Casavecchia, G., Cadeddu Dessalvi, C., Bergamini, C., Zito, C., Madaudo, C., Madonna, R., Cameli, M., and Novo, G. (2023). Atrial Strain Assessment for the Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Women (The STRANO STUDY: Atrial Strain in Cardio-Oncology). J. Clin. Med., 12.","DOI":"10.3390\/jcm12227127"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.echo.2020.10.002","article-title":"Usefulness of Stress Echocardiography in the Management of Patients Treated with Anticancer Drugs","volume":"34","author":"Novo","year":"2021","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s10554-021-02243-x","article-title":"Feasibility of semi-recumbent bicycle exercise Doppler echocardiography for the evaluation of the right heart and pulmonary circulation unit in different clinical conditions: The RIGHT heart international NETwork (RIGHT-NET)","volume":"37","author":"Ferrara","year":"2021","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12947-021-00238-1","article-title":"A multicentric quality-control study of exercise Doppler echocardiography of the right heart and the pulmonary circulation. The RIGHT Heart International NETwork (RIGHT-NET)","volume":"19","author":"Ferrara","year":"2021","journal-title":"Cardiovasc. Ultrasound."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijcard.2005.07.029","article-title":"Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity","volume":"111","author":"Civelli","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1442-200X.2006.02210.x","article-title":"Evaluation of cardiac reserved function by high-dose dobutamine stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer","volume":"48","author":"Hamada","year":"2006","journal-title":"Pediatr. Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1525-2167(03)00017-9","article-title":"Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity","volume":"4","author":"Bountioukos","year":"2003","journal-title":"Eur. J. Echocardiogr."},{"key":"ref_42","first-page":"775","article-title":"Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib","volume":"18","author":"Sen","year":"2013","journal-title":"J. BUON"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ferrara, F., Capuano, F., Cocchia, R., Ranieri, B., Contaldi, C., Lacava, G., Capone, V., Chianese, S., Rega, S., and Annunziata, R. (2021). Reference Ranges of Left Ventricular Hemodynamic Forces in Healthy Adults: A Speckle-Tracking Echocardiographic Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245937"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"ehae666.3197","DOI":"10.1093\/eurheartj\/ehae666.3197","article-title":"Can haemodynamic force analysis be used to identify cancer treatment-related cardiac dysfunction? A comparison with strain and ejection fraction","volume":"45","author":"Sivaraj","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1053\/euhj.2000.2011","article-title":"Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?","volume":"21","author":"Bellenger","year":"2000","journal-title":"Eur. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11897-020-00455-1","article-title":"Traditional and novel imaging of right ventricular function in patients with heart failure and reduced ejection fraction","volume":"17","author":"Sciaccaluga","year":"2020","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/CIRCULATIONAHA.117.027740","article-title":"Association of Feature-Tracking Cardiac Magnetic Resonance Imaging Left Ventricular Global Longitudinal Strain with All-Cause Mortality in Patients with Reduced Left Ventricular Ejection Fraction","volume":"135","author":"Romano","year":"2017","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/COC.0b013e31829e19be","article-title":"Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy","volume":"38","author":"Lunning","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2018.03.041","article-title":"Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy","volume":"261","author":"Ong","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/heartjnl-2019-316297","article-title":"Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity","volume":"106","author":"Lambert","year":"2020","journal-title":"Heart"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e004560","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","article-title":"Left Ventricular Mass Change After Anthracycline Chemotherapy","volume":"11","author":"Jordan","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamacardio.2023.0494","article-title":"Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women with Breast Cancer","volume":"8","author":"Thavendiranathan","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e003584","DOI":"10.1161\/CIRCIMAGING.115.003584","article-title":"Characterization of the Changes in Cardiac Structure and Function in Mice Treated with Anthracyclines Using Serial Cardiac Magnetic Resonance Imaging","volume":"9","author":"Farhad","year":"2016","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2015.08.153","article-title":"Assessment of the relationships between left ventricular filling pressures and longitudinal dysfunction with myocardial fibrosis in uncomplicated hypertensive patients","volume":"202","author":"Contaldi","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1532-429X-15-48","article-title":"Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: Relationship to exercise capacity, cumulative dose and remodeling","volume":"15","author":"Tham","year":"2013","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ehf2.12277","article-title":"Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy","volume":"5","author":"Muehlberg","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","article-title":"Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient","volume":"11","author":"Plana","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/ehjci\/jeaa345","article-title":"Role of cardiovascular magnetic resonance imaging in cardio-oncology","volume":"22","author":"Saunderson","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amjcard.2012.11.022","article-title":"Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracyclinebased chemotherapy","volume":"111","author":"Neilan","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jcmg.2016.06.006","article-title":"Progressive 3-Month Increase in LV Myocardial ECV After Anthracycline-Based Chemotherapy","volume":"10","author":"Jordan","year":"2017","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcmg.2018.05.012","article-title":"Anthracycline Therapy Is Associated with Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease","volume":"11","author":"Shah","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00330-011-2345-6","article-title":"Left and right ventricle assessment with Cardiac CT: Validation study vs. Cardiac MR","volume":"22","author":"Maffei","year":"2012","journal-title":"Eur. Radiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.amjcard.2013.11.016","article-title":"Meta-analysis of global left ventricular function comparing multidetector computed tomography with cardiac magnetic resonance imaging","volume":"113","author":"Sharma","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_65","first-page":"635","article-title":"Cardiac computed tomography in cardiooncology: JACC: CardioOncology primer","volume":"3","author":"Yang","year":"2021","journal-title":"Cardio Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcct.2022.09.002","article-title":"Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS)","volume":"17","author":"Yang","year":"2023","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1253\/circj.CJ-20-1288","article-title":"Usefulness of Cardiac Computed Tomography in the Diagnosis of Anti-Cancer Therapy-Related Cardiac Dysfunction-Consistency with Magnetic Resonance Imaging","volume":"85","author":"Sueta","year":"2021","journal-title":"Circ. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13244-022-01224-5","article-title":"Myocardial extracellular volume derived from contrast-enhanced chest computed tomography for longitudinal evaluation of cardiotoxicity in patients with breast cancer treated with anthracyclines","volume":"13","author":"Tu","year":"2022","journal-title":"Insights Imaging"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jat.782","article-title":"Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats","volume":"21","author":"Othman","year":"2001","journal-title":"J. Appl. Toxicol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1254\/jjp.88.183","article-title":"Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters","volume":"88","author":"Okumura","year":"2002","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1388-9842(02)00091-0","article-title":"Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin","volume":"4","author":"Vaynblat","year":"2002","journal-title":"Eur. J. Heart Fail."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1385\/CT:3:4:319","article-title":"Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity","volume":"3","author":"Boucek","year":"2003","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ehj.2004.06.003","article-title":"Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology","volume":"25","author":"Swedberg","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejphar.2013.06.040","article-title":"Enalaprilat increases PPAR\u03b2\/\u03b4 expression, without influence on PPAR\u03b1 and PPAR\u03b3, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy","volume":"714","author":"Cernecka","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_75","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: A \u2019dual-hit\u2019","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"H934","DOI":"10.1152\/ajpheart.00206.2017","article-title":"Inhibitory actions of the NRG-1\/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung","volume":"313","author":"Vermeulen","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/VHRM.S69641","article-title":"Breast cancer therapy and cardiovascular risk: Focus on trastuzumab","volume":"11","author":"Sandoo","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10549-009-0730-5","article-title":"Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy","volume":"122","author":"Blaes","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/COC.0000000000000389","article-title":"Prevention of trastuzumab and anthracyclineinduced cardiotoxicity using angiotensin-converting enzyme inhibitors or beta-blockers in older adults with breast cancer","volume":"41","author":"Wittayanukorn","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/imj.16437","article-title":"Prevention of anthracycline and trastuzumab-induced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: A narrative systematic review of randomised controlled trials","volume":"54","author":"Lee","year":"2024","journal-title":"Intern. Med. J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000492942","article-title":"Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen","volume":"63","author":"Gruszka","year":"2018","journal-title":"Chemotherapy"},{"key":"ref_84","first-page":"1052","article-title":"Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?","volume":"18","author":"Radulescu","year":"2013","journal-title":"J. BUON"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"487.e1","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/etm.2011.305","article-title":"Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction","volume":"2","author":"Dessi","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/molpharm.121.000359","article-title":"\u03b2-Arrestin-Biased Allosteric Modulator Potentiates Carvedilol-Stimulated \u03b2 Adrenergic Receptor Cardioprotection","volume":"100","author":"Wang","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1161\/01.CIR.0000018605.14470.DD","article-title":"Carvedilol decreases elevated oxidative stress in human failing myocardium","volume":"105","author":"Nakamura","year":"2002","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/taap.2002.9532","article-title":"Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy","volume":"185","author":"Santos","year":"2002","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1161\/01.CIR.0000130917.12959.04","article-title":"Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts","volume":"109","author":"Asanuma","year":"2004","journal-title":"Circulation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"14555","DOI":"10.1073\/pnas.0804745105","article-title":"Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation","volume":"105","author":"Kim","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Erickson, C.E., Gul, R., Blessing, C.P., Nguyen, J., Liu, T., Pulakat, L., Bastepe, M., Jackson, E.K., and Andresen, B.T. (2013). The \u03b2-blocker Nebivolol Is a GRK\/\u03b2-arrestin biased agonist. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071980"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13063-019-3963-6","article-title":"Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: Study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial)","volume":"21","author":"Carrasco","year":"2020","journal-title":"Trials"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: A double-blind randomized trial","volume":"134","author":"Hosseini","year":"2016","journal-title":"Cardiology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8367444","DOI":"10.1155\/2022\/8367444","article-title":"Beta-blockers for primary prevention of anthracycline-induced cardiac toxicity: An updated meta-analysis of randomized clinical trials","volume":"2022","author":"Attar","year":"2022","journal-title":"Cardiovasc. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.ihj.2018.06.011","article-title":"Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin","volume":"70","author":"Abuosa","year":"2018","journal-title":"Indian Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","article-title":"Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol","volume":"24","author":"Huang","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/HYPERTENSIONAHA.108.121954","article-title":"Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation","volume":"53","author":"Wei","year":"2009","journal-title":"Hypertension"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective Strategy for Patients with Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s11010-021-04152-y","article-title":"Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer","volume":"476","author":"Varghese","year":"2021","journal-title":"Mol. Cell Biochem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1574887118666230118102252","article-title":"Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials","volume":"18","author":"Keshavarzian","year":"2023","journal-title":"Rev. Recent Clin. Trials."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Gheorghe, G., Toth, P.P., Bungau, S., Behl, T., Ilie, M., Pantea Stoian, A., Bratu, O.G., Bacalbasa, N., Rus, M., and Diaconu, C.C. (2020). Cardiovascular Risk and Statin Therapy Considerations in Women. Diagnostics, 10.","DOI":"10.3390\/diagnostics10070483"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Jiang, R., Lou, L., Shi, W., Chen, Y., Fu, Z., Liu, S., Sok, T., Li, Z., Zhang, X., and Yang, J. (2024). Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810177"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FJC.0000000000000646","article-title":"Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways","volume":"73","author":"Gao","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Pecoraro, M., Marzocco, S., Belvedere, R., Petrella, A., Franceschelli, S., and Popolo, A. (2023). Simvastatin Reduces Doxorubicin-Induced Cardiotoxicity: Effects beyond Its Antioxidant Activity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087573"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9603271221111440","DOI":"10.1177\/09603271221111440","article-title":"Simvastatin cardioprotection in cyclophosphamide-induced toxicity via the modulation of inflammasome\/caspase 1\/interleukin1\u03b2 pathway","volume":"41","author":"Refaie","year":"2022","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biopha.2017.06.033","article-title":"Targeting proinflammatory cytokines, oxidative stress, TGF-\u03b21 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity","volume":"93","author":"Kabel","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.echo.2020.05.021","article-title":"Protective Effects of Statin and Angiotensin Receptor Blocker in a Rat Model of Doxorubicin- and Trastuzumab-Induced Cardiomyopathy","volume":"33","author":"Cho","year":"2020","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Muhammad, R.N., Sallam, N., and El-Abhar, H.S. (2020). Activated ROCK\/Akt\/eNOS and ET-1\/ERK pathways in 5-fluorouracil-induced cardiotoxicity: Modulation by simvastatin. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-71531-8"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2174\/1389450111009011395","article-title":"Modulation of the Rho\/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity","volume":"11","author":"Monceau","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Ait-Aissa, K., Leng, L.N., Lindsey, N.R., Guo, X., Juhr, D., Koval, O.M., and Grumbach, I.M. (2023). Mechanisms by which statins protect endothelial cells from radiation-induced injury in the carotid artery. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1133315"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e00145","DOI":"10.1002\/prp2.145","article-title":"Simvastatin mitigates increases in risk factors for and the occurrence of cardiac disease following 10 Gy total body irradiation","volume":"3","author":"Lenarczyk","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00395-024-01046-0","article-title":"Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin","volume":"120","author":"Efentakis","year":"2024","journal-title":"Basic Res. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: An observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cjca.2014.11.020","article-title":"Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function","volume":"31","author":"Chotenimitkhun","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"101885","DOI":"10.1016\/j.cpcardiol.2023.101885","article-title":"Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis","volume":"48","author":"Titus","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cjca.2018.11.028","article-title":"Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy","volume":"35","author":"Michalowska","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6276438","DOI":"10.1155\/2018\/6276438","article-title":"Alleviation of Drugs and Chemicals Toxicity: Biomedical Value of Antioxidants","volume":"2018","author":"Aleya","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., and Tang, H. (2022). Chronic inflammation, cancer development and immunotherapy. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1040163"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Nigam, M., Mishra, A.P., Deb, V.K., Dimri, D.B., Tiwari, V., Bungau, S.G., Bungau, A.F., and Radu, A.F. (2023). Evaluation of the association of chronic inflammation and cancer: Insights and implications. Biomed. Pharmacother., 164.","DOI":"10.1016\/j.biopha.2023.115015"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-Receptor Inhibition with Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients with Early Breast Cancer: A Randomized Clinical Trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","article-title":"Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy","volume":"17","author":"Janbabai","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"10.1056","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"104577","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials","volume":"51","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10741-019-09906-x","article-title":"Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: A meta-analysis of randomized controlled trials","volume":"26","author":"Fang","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","article-title":"Prevention of anthracycline-induced cardiotoxicity: A systematic review and meta-analysis","volume":"16","author":"Caspani","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10741-023-10328-z","article-title":"ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: A systematic review and meta-analysis","volume":"28","author":"Gao","year":"2023","journal-title":"Heart Fail. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Contaldi, C., De Vivo, S., Martucci, M.L., D\u2019Onofrio, A., Ammendola, E., Nigro, G., Errigo, V., Pacileo, G., and Masarone, D. (2022). Effects of Cardiac Contractility Modulation Therapy on Right Ventricular Function: An Echocardiographic Study. Appl. Sci., 12.","DOI":"10.3390\/app12157917"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"9","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril-valsartan in cancer patients with heart failure","volume":"7","author":"Mitroi","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_143","first-page":"24","article-title":"Use of Sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardiooncology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"ehac544","DOI":"10.1093\/eurheartj\/ehac544.2590","article-title":"Use of emgliflozine in cardiotoxicity treatment. EMPACARD-treatment registry. Six-months follow-up","volume":"43","author":"Daniele","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.36660\/abc.20201006","article-title":"Brazilian Cardio-oncology Guideline\u20142020","volume":"115","author":"Hajjar","year":"2020","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Oda, H., Hayashi, Y., Oyanagi, N., Tanaka, K., Ozaki, K., Kashiwa, A., Hosaka, Y., Tsuchida, K., and Takahashi, K. (2024). Add-on multidrug treatment based on quadruple therapy successfully treated worsening heart failure caused by anthracycline-induced cardiomyopathy in a survivor of cancer as a young adult: A case report. BMC Cardiovasc. Disord., 24.","DOI":"10.1186\/s12872-024-04189-z"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Shi, H., Lu, H., Zheng, Y., Pu, P., Wei, L., Hu, D., Tang, H., and Wang, L. (2024). Bioinformatics and experimental studies jointly reveal that Sacubitril Valsartan improves myocardial oxidative stress and inflammation by regulating the MAPK signaling pathway to treat chemotherapy related cardiotoxicity. Biochem. Biophys. Res. Commun., 690.","DOI":"10.1016\/j.bbrc.2023.149244"},{"key":"ref_148","first-page":"1898","article-title":"Sacubitril\/valsartan attenuated myocardial inflammation, fibrosis, apoptosis and promoted autophagy in doxorubicin-induced cardiotoxicity mice via regulating the AMPK\u03b1-mTORC1 signaling pathway","volume":"480","author":"Hu","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Mecinaj, A., Vinje-Jakobsen, V., Ngo, D.T.M., Sverdlov, A.L., and Myhre, P.L. (2025). The SARAH trial: More evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity. Heart Fail Rev.","DOI":"10.1007\/s10741-025-10495-1"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/ehf2.14466","article-title":"Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): Design and rationle of the randomized trial","volume":"10","author":"Tajstra","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00204-022-03298-y","article-title":"Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3","volume":"96","author":"Chang","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Hsieh, P.L., Chu, P.M., Cheng, H.C., Huang, Y.T., Chou, W.C., Tsai, K.L., and Chan, S.H. (2022). Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231710146"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"106949","DOI":"10.1016\/j.vph.2021.106949","article-title":"Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy","volume":"142","author":"Madonna","year":"2022","journal-title":"Vascul. Pharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","article-title":"SGLT2i and primary prevention of cancer therapy\u2013related cardiac dysfunction in patients with diabetes","volume":"6","author":"Bhatti","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated with Anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The Association of Sodium-Glucose Cotransporter 2 Inhibitors with Cardiovascular Outcomes in Anthracycline-Treated Patients with Cancer","volume":"5","author":"Carrasco","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 Inhibitor Use and Risk of Clinical Events in Patients with Cancer Therapy-Related Cardiac Dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_159","first-page":"58","article-title":"Use of EMPAgliflozin in the prevention of CARDiotoxicity: The EMPACARD\u2014PILOT trial","volume":"10","author":"Daniele","year":"2024","journal-title":"Cardiooncology"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Berretta, M., Bisceglia, I., Giacobbe, I., Iovine, M., Giordano, V., Arianna, R., Barbato, M., Izzo, F., and Maurea, C. (2024). The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients. Cancers, 16.","DOI":"10.3390\/cancers16081487"},{"key":"ref_161","first-page":"10","article-title":"Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: An updated systematic review & network meta-analysis","volume":"9","author":"Mir","year":"2023","journal-title":"Cardiooncology"},{"key":"ref_162","first-page":"ii31","article-title":"Soluble guanylate cyclase activator vericiguat prevents anthracycline\u2013mediated cardiotoxicity and sarcopenia through no\u2013sgc\u2013cgmp\u2013nlrp3 pathway: Potential application in cancer patients","volume":"26","author":"Quagliariello","year":"2024","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Dozic, S., Howden, E.J., Bell, J.R., Mellor, K.M., Delbridge, L.M.D., and Weeks, K.L. (2023). Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy. Cells, 12.","DOI":"10.3390\/cells12091312"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.rehab.2021.101485","article-title":"Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: A randomized controlled trial","volume":"65","author":"Chung","year":"2022","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-017-4554-4","article-title":"The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: A RCT","volume":"167","author":"Kirkham","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/eurjpc\/zwab006","article-title":"The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: Systematic review","volume":"29","author":"Murray","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11897-024-00662-0","article-title":"Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction","volume":"21","author":"Wernhart","year":"2024","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.122.062814","article-title":"Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study","volume":"147","author":"Foulkes","year":"2023","journal-title":"Circulation"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"15347354241291176","DOI":"10.1177\/15347354241291176","article-title":"Effects of Physical Activity on Cardiotoxicity and Cardio respiratory Function in Cancer Survivors Undergoing Chemotherapy: A Systematic Review and Meta-Analysis","volume":"23","author":"Chen","year":"2024","journal-title":"Integr. Cancer Ther."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pcad.2024.02.002","article-title":"Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial","volume":"85","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1534735419843999","DOI":"10.1177\/1534735419843999","article-title":"Effects of Calorie Restriction and Voluntary Exercise on Doxorubicin-Induced Cardiotoxicity","volume":"18","author":"Hall","year":"2019","journal-title":"Integr. Cancer Ther."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Stephenson, E., Mclaughlin, M., Bray, J.W., Saxton, J.M., and Vince, R.V. (2024). Nutrition Modulation of Cardiotoxicity in Breast Cancer: A Scoping Review. Nutrients, 16.","DOI":"10.3390\/nu16213777"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Muckiene, G., Vaitiekus, D., Zaliaduonyte, D., Bartnykaite, A., Plisiene, J., Zabiela, V., Juozaityte, E., and Jurkevicius, R. (2023). The Impact of Polymorphisms in ATP-Binding Cassette Transporter Genes on Anthracycline-Induced Early Cardiotoxicity in Patients with Breast Cancer. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10060232"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaccao.2023.11.008","article-title":"Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes","volume":"6","author":"Fonoudi","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/tpj.2015.63","article-title":"Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia","volume":"16","author":"Krajinovic","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr. Blood Cancer."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Hurkmans, E.G.E., Brand, A.C.A.M., Verdonschot, J.A.J., Te Loo, D.M.W.M., and Coenen, M.J.H. (2022). Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: A systematic review. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10434-5"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.reprotox.2021.04.003","article-title":"Mechanisms of doxorubicin-mediated reproductive toxicity\u2014A review","volume":"102","author":"Mohan","year":"2021","journal-title":"Reprod. Toxicol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes\u2014A report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1258\/ebm.2010.010206","article-title":"CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells","volume":"236","author":"Wang","year":"2011","journal-title":"Exp. Biol. Med."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Jeong, S.Y., Park, B.W., Kim, J., Lee, S., You, H., Lee, J., Lee, S., Park, J.H., Kim, J., and Sim, W. (2024). Hyaluronic acid stimulation of stem cells for cardiac repair: A cell-free strategy for myocardial infarct. J. Nanobiotechnology, 22.","DOI":"10.1186\/s12951-024-02410-x"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.2013.50.3557","article-title":"Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: A report from the children\u2019s oncology group","volume":"32","author":"Wang","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","article-title":"Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity","volume":"18","author":"Beauclair","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41467-018-03961-y","article-title":"Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA","volume":"9","author":"Zemmour","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1161\/CIRCULATIONAHA.123.068358","article-title":"Rectifying METTL4-Mediated N6-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure","volume":"150","author":"Zhang","year":"2024","journal-title":"Circulation"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Bauer, M.A., Todorova, V.K., Stone, A., Carter, W., Plotkin, M.D., Hsu, P.C., Wei, J.Y., Su, J.L., and Makhoul, I. (2021). Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13246291"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e019628","DOI":"10.1161\/JAHA.120.019628","article-title":"Machine Learning-Based Risk Assessment for Cancer Therapy-Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients","volume":"9","author":"Zhou","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12012-021-09708-4","article-title":"Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy","volume":"22","author":"Li","year":"2022","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s10554-024-03178-9","article-title":"Artificial intelligence-derived left ventricular strain in echocardiography in patients treated with chemotherapy","volume":"40","author":"Kuwahara","year":"2024","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.122.062646","article-title":"Detection of Left Ventricular Systolic Dysfunction from Electrocardiographic Images","volume":"148","author":"Sangha","year":"2023","journal-title":"Circulation"},{"key":"ref_191","first-page":"e011504","article-title":"Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images","volume":"18","author":"Oikonomou","year":"2024","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_192","first-page":"16","article-title":"A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research","volume":"8","author":"Brown","year":"2022","journal-title":"Cardiooncology"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-S\u00e1nchez, R., Reinal, I., Peir\u00f3-Molina, E., Buigues, M., Tejedor, S., Hern\u00e1ndiz, A., Selva, M., Herv\u00e1s, D., Ca\u00f1ada, A.J., and Dorronsoro, A. (2022). MicroRNA-4732-3p Is Dysregulated in Breast Cancer Patients with Cardiotoxicity, and Its Therapeutic Delivery Protects the Heart from Doxorubicin-Induced Oxidative Stress in Rats. Antioxidants, 11.","DOI":"10.3390\/antiox11101955"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Pillai, S.S., Pereira, D.G., Bonsu, G., Chaudhry, H., Puri, N., Lakhani, H.V., Tirona, M.T., Sodhi, K., and Thompson, E. (2022). Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.953178"},{"key":"ref_196","first-page":"340","article-title":"The subcellular localization of defensins and myeloperoxidase in human neutrophils: Immunocytochemical evidence for azurophil granule heterogeneity","volume":"125","author":"Oren","year":"1995","journal-title":"J. Lab. Clin. Med."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Lakhani, H.V., Pillai, S.S., Zehra, M., Dao, B., Tirona, M.T., Thompson, E., and Sodhi, K. (2021). Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-87209-8"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/08820139.2021.1882486","article-title":"Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study","volume":"51","author":"Alves","year":"2022","journal-title":"Immunol. Investig."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/clc.23966","article-title":"High neutrophil-to-lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracycline","volume":"46","author":"Baruch","year":"2023","journal-title":"Clin. Cardiol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12265-019-09897-y","article-title":"Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Cardiotoxicity in Patients with Breast Cancer","volume":"13","author":"Asnani","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_201","first-page":"17","article-title":"Anthracycline cardiotoxicity: Current methods of diagnosis and possible role of 18F-FDG PET\/CT as a new biomarker","volume":"9","author":"Becker","year":"2023","journal-title":"Cardiooncology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2016.01.002","article-title":"Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity","volume":"32","author":"Gu","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ncb1007-1102","article-title":"Autophagosome formation: Core machinery and adaptations","volume":"9","author":"Xie","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1007\/s10565-023-09831-8","article-title":"Targeting autophagy with SAR405 alleviates doxorubicin-induced cardiotoxicity","volume":"39","author":"Sun","year":"2023","journal-title":"Cell Biol. Toxicol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/3\/471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:18Z","timestamp":1760028858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/3\/471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":204,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["life15030471"],"URL":"https:\/\/doi.org\/10.3390\/life15030471","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]}}}